Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medimetriks Pharmaceuticals, a developer and marketer of prescription skincare products, has entered into a licensing agreement with Perrigo Company, a healthcare supplier, for the US marketing rights to Centany ointment and two prescription keratolytic brands.
Subscribe to our email newsletter
Patented through 2018, Centany represents an important step in Medimetriks’ plan to commercialize patent-protected therapies for the dermatology and podiatry markets that offer important patient benefits. Medimetriks plans to launch Centany in early 2009, with the two additional products following shortly thereafter.
Previously marketed by Johnson & Johnson’s OrthoNeutrogena professional division, Centany is indicated for the topical treatment of impetigo due to Straphylococcus aureus and Streptococcus pyogenes.
The two prescription keratolytic brands are urea-based therapies indicated for the treatment of severe dry skin. They are offered in delivery systems that are gaining wide acceptance in the dermatology and podiatry markets and are both patent pending.
Bradley Glassman, president and CEO of Medimetriks, said: “We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core dermatology and podiatry audiences and their patients.”